


# Molecular Diagnostics in Clinical Practice

November 6-7, 2020

Location: ONLINE



## Course Overview

**Molecular diagnostics** is one of the most dynamic and transformative areas in health care. Our ability to properly and successfully utilize this information in routine clinical practice relies on familiarity with the technology, the factors that impact test performance and specific interpretation of results in the context of all available clinicopathologic information.

This virtual course features a comprehensive overview of the current landscape of molecular diagnostics as it applies to the diagnosis, risk assessment, management and monitoring of patients with solid tumors and hematologic neoplasms. Through a case-based approach, participants will also learn about current and evolving clinically relevant biomarkers, the importance of proper test utilization, specimen handling and interpretation of results in the context of the clinical and pathologic presentation. All sessions will be recorded and will be made available for future viewing and reference to those registered for the course.

## Registration

*Admission free for MSK staff*

	Early*	General
Physicians (MDs, PhDs and DOs)	\$250	\$300
Advanced Practice Providers	\$200	\$250
Nurses, Techs, and Other Healthcare Providers	\$100	\$150
Residents and Fellows	\$25	\$75
Industry Professionals	n/a	\$435

\*Early registration deadline is October 23, 2020

To register, go to: [www.mskcc.org/mskmlpath](http://www.mskcc.org/mskmlpath)

### Contact

**Sarah B. Virgo**

Assistant Manager, Pathology Communications  
Department of Pathology  
Memorial Sloan Kettering Cancer Center  
1275 York Avenue, H-504  
New York, New York 10065  
(212) 639-5696 | [cooks@mskcc.org](mailto:cooks@mskcc.org)

### Educational Objectives

- Provide up-to-date information on basic and advanced molecular diagnostic methods
- Provide up-to-date information on advantages, pitfalls and factors that impact results of molecular testing
- Provide up-to-date information on classification and stratification of patients with solid tumors and hematologic malignancies based on current and evolving molecular biomarkers
- Provide an overview on how to select a testing method based on the sample and the clinical scenario

### Intended Audience

Clinicians, pathologists, medical trainees and other health care professionals who have an interest in this subject matter and utilize molecular diagnostic tests for diagnosis and management of their patients.

### Course Design


The course will be offered in virtual format only with short, high yield overviews of molecular testing methods and applications to major solid tumor and hematologic malignancies. Participants will be able to submit questions that will be answered at the end of each block session. All sessions will be recorded and will be made available for future reference to all registrants.

### Evaluation

A course evaluation survey sent out electronically will provide attendees with the opportunity to review the sessions and the speakers and to identify future educational needs.

### Accreditation Statement

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.




Memorial Sloan Kettering  
Cancer Center™

Department of Pathology  
1275 York Avenue, H-504  
New York, NY 10065

## Molecular Diagnostics in Clinical Practice

November 6-7, 2020

Location: ONLINE



## Molecular Diagnostics in Clinical Practice

November 6-7, 2020

Location: ONLINE



Memorial Sloan Kettering  
Cancer Center

## Course Director



**Maria E. Arcila MD**  
*Laboratory Director,  
Diagnostic Molecular  
Pathology Laboratory*

## Organizing Committee




**Caleb Ho,  
MD**



**Kseniya  
Petrova-Drus,  
MD, PhD**



**Dara  
Ross, MD**



**JinJuan Yao,  
MD, PhD**

## Course Faculty

Hikmat Al-Ahmadie, MD	Rose Brannon, PhD	Mark Ewalt, MD	Diana Mandelker, MD, PhD	Wenbin Xiao, MD, PhD
Tejus Bale, MD, PhD	Jason Chang, MD	Meera Hameed, MD	Khedoudja Nafa, PharmD, PhD	Soo-Ryum Yang, MD
Ryma Benayed, PhD	Sarah Chiang, MD	Jaclyn Hechtman, MD	Andres Quesada, MD	Ahmet Zehir, PhD
Jamal Benhamida, MD	Snjezana Dogan, MD	Marc Ladanyi, MD	Efsevia Vakiani, MD, PhD	Menglei Zhu, MD, PhD
Ozge Birsoy, PhD	Benjamin Durham, MD	Ying Liu, MD, PhD	Chad Vanderbilt, MD	

### Faculty Disclosure

It is the policy of MSK to make every effort to ensure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it sponsors as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity sponsored by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigatory use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

### AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **16.5 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Outcomes Measurement Survey

Six months after the end of the course an Outcomes Measurement Survey will be sent to all participants to help us determine what positive impacts have been made on participant practice as a result of the course.

## Friday, November 6th

8:30–9:00 am	Clinical Cancer Genomics: A New Pillar in the Management of the Cancer Patient <i>Marc Ladanyi, MD</i>
9:00–9:30 am	Basic Review of Molecular Methods <i>Maria E. Arcila, MD</i>
9:30–10:00 am	Assessment of Fusions and Structural Rearrangements <i>Ryma Benayed, PhD</i>
10:00–10:30 am	Cell-Free DNA Assessment <i>Rose Brannon, PhD</i>
10:30–11:00 am	Assessment of Methylation <i>Jamal Benhamida, MD</i>
11:00–11:10 am	Break
11:10–11:40 am	The Role of Bioinformatics <i>Ahmet Zehir, PhD</i>
11:40–12:10 pm	Germline Testing <i>Diana Mandelker, MD, PhD</i>
12:10–12:20 pm	Questions for Faculty
12:20–1:00 pm	Break
Applications of Molecular Testing to Solid Tumors <i>Session Chairs: Dara Ross, MD and Khedoudja Nafa, PharmD, PhD</i>	
1:00–1:30 pm	Lung Cancer <i>Jason Chang, MD</i>

1:30–2:00 pm	Gastrointestinal Malignancies <i>Efsevia Vakiani, MD, PhD</i>
2:00–2:30 pm	Breast Cancer <i>Dara Ross, MD</i>
2:30–3:00 pm	Central Nervous System Neoplasms <i>Tejus Bale, MD, PhD</i>
3:00–3:15 pm	Questions for Faculty
3:15–3:30 pm	Break
3:30–4:00 pm	Head and Neck Tumors <i>Snjezana Dogan, MD</i>
4:00–4:30 pm	Soft Tissue and Bone Malignancies <i>Meera Hameed, MD</i>
4:30–5:00 pm	Gynecologic Tumors <i>Sarah Chiang, MD</i>
5:00–5:30 pm	Urologic Malignancies <i>Hikmat Al-Ahmadie, MD</i>
5:30–5:45 pm	Questions for Faculty

## Saturday, November 7th

Applications of Molecular Testing to Hematologic Malignancies <i>Session Chairs: Caleb Ho, MD and Kseniya Petrova-Drus, MD, PhD</i>	
8:30–9:00 am	Acute Myeloid Malignancies <i>Wenbin Xiao, MD, PhD</i>

9:00–9:30 am	Acute Lymphoid Leukemias and Leukemias of Ambiguous Lineage <i>Kseniya Petrova-Drus, MD, PhD</i>
9:30–10:00 am	Chronic Myeloid Neoplasms <i>Maria Arcila, MD</i>
10:00–10:10 am	Break
10:10–10:40 am	Mature B-Cell Lymphomas <i>Caleb Ho, MD</i>
10:40–11:10 am	Mature T-Cell Lymphomas <i>Andres Quesada, MD</i>
11:10–11:40 pm	Histiocytic/Dendritic and Mast Cell Neoplasms <i>Benjamin Durham, MD</i>
11:40–12:10 pm	Hematologic Malignancies Associated with Germline Alterations <i>Ozge Birsoy, PhD</i>
12:10–12:30 pm	Questions for Morning Session
12:30–1:00 pm	Break
Advanced Topics in Molecular Testing <i>Session Chairs: JinJuan Yao, MD, PhD and Chad Vanderbilt, MD</i>	

1:00–1:30 pm	Clonality Testing for Characterization and Monitoring of Lymphoid Neoplasms <i>Caleb Ho, MD</i>
1:30–2:00 pm	High Sensitivity and Minimal Residual Disease Assessment <i>Mark Ewalt, MD</i>

2:00–2:30 pm	Role of Infections and the Microbiome in the Development of Neoplasia <i>Chad Vanderbilt, MD</i>
2:30–2:50 pm	Tumor Mutation Burden <i>Ahmet Zehir, PhD</i>
2:50–3:10 pm	Microsatellite Instability <i>Jaclyn Hechtman, MD</i>
3:10–3:25 pm	Questions for Faculty
3:25–3:40 pm	Break
3:40–4:00 pm	Quality Assurance and Quality Control in Molecular Diagnostics <i>JinJuan Yao, MD, PhD</i>
4:00–4:20 pm	Advanced Case Studies: Solid Tumor <i>Jaclyn Hechtman, MD</i>
4:20–4:40 pm	Advanced Case Studies: Solid Tumor <i>Soo-Ryum Yang, MD</i>
4:40–5:00 pm	Advanced Case Studies: Hematologic Malignancies <i>Ying Liu, MD, PhD</i>
5:00–5:20 pm	Advanced Case Studies: Hematologic Malignancies <i>Menglei Zhu, MD, PhD</i>
5:20–5:40 pm	Questions for the Faculty and Final Remarks